Solid Biosciences
SLDB
77 hedge funds and large institutions have $83.2M invested in Solid Biosciences in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 35 reducing their positions, and 15 closing their positions.
532% more call options, than puts
Call options by funds: $120K | Put options by funds: $19K
0.38% less ownership
Funds ownership: 4.57% → 4.18% (-0.38%)
6% less funds holding
Funds holding: 82 → 77 (-5)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
37% less capital invested
Capital invested by funds: $132M → $83.2M (-$49M)
60% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$2.54M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$1.1M |
| 3 |
Renaissance Technologies
New York
|
+$777K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$366K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$353K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.81M |
| 2 |
Millennium Management
New York
|
-$644K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$545K |
| 4 |
BlackRock
New York
|
-$507K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$475K |
SLDB Hedge Fund Activity: Q1 2022 in Review
77 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q1 2022, worth a combined $83.2M — down 37% from $132M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SLDB and 11 opened new positions — a net loss of 4 holders — while 35 trimmed existing stakes and 14 added.
The largest buyer was Boxer Capital, adding an estimated $2.54M. The largest seller was EcoR1 Capital, cutting an estimated $7.81M.
- 77 institutional investors held Solid Biosciences (SLDB) as of Q1 2022, down from 82 in Q4 2021.
- Funds reported $83.2M of Solid Biosciences stock for Q1 2022, down 37% quarter-over-quarter.
- 11 funds opened new Solid Biosciences positions in Q1 2022 and 15 closed out, a net change of -4 holders.
- The largest Solid Biosciences buyer in Q1 2022 was Boxer Capital, an estimated $2.54M added.
- The largest Solid Biosciences seller in Q1 2022 was EcoR1 Capital, an estimated $7.81M sold.
Based on aggregated 13F filings for Q1 2022.